Exclusive Summary

• Backed by US-FDA approval and dual EU-EMA/US-FDA GMP certifications, enabling immediate commercialization in the US and fast-track market access via reliance pathways globally.
• Features high-barrier extended-release (MUPS) formulation technologies with a comprehensive dosage range (23.8mg to 190mg), establishing a strong competitive moat against conventional generic suppliers.
• Serves as a WHO Essential Medicine and strict first-line guideline therapy, guaranteeing rigid, long-term market demand from an immense global population of over 1.3 billion hypertension and heart failure patients.
• Capitalizes on China's large-scale, resilient manufacturing infrastructure to offer distributors significant cost advantages and aggressive pricing power over the originator and Western generic peers in public tenders.